Detalhe da pesquisa
1.
Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.
Nature
; 608(7923): 609-617, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35948633
2.
Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.
Nature
; 609(7929): E13, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-36050473
3.
Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing.
Br J Cancer
; 127(8): 1540-1549, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35871236
4.
Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment.
Clin Immunol
; 218: 108517, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32585295
5.
Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase δ Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy.
J Pharmacol Exp Ther
; 374(1): 211-222, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32345620
6.
INCB040093 Is a Novel PI3Kδ Inhibitor for the Treatment of B Cell Lymphoid Malignancies.
J Pharmacol Exp Ther
; 364(1): 120-130, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29127109
7.
The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.
Blood
; 126(13): 1551-4, 2015 Sep 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-26228487
8.
Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis.
Haematologica
; 102(2): 327-335, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27789678
9.
Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.
Ann Hematol
; 96(7): 1113-1120, 2017 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-28456851
10.
The Janus kinase 2 inhibitor fedratinib inhibits thiamine uptake: a putative mechanism for the onset of Wernicke's encephalopathy.
Drug Metab Dispos
; 42(10): 1656-62, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25063672
11.
Global Expanded Access Program for Pemigatinib in Patients with Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma and Fibroblast Growth Factor Receptor Gene Alterations.
Cancer Res Treat
; 2024 Feb 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38351684
12.
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.
Blood
; 115(15): 3109-17, 2010 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20130243
13.
Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis.
Blood
; 115(14): 2919-27, 2010 Apr 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-20154217
14.
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity.
Blood
; 115(17): 3520-30, 2010 Apr 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-20197554
15.
Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.
J Immunol
; 184(9): 5298-307, 2010 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20363976
16.
Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling.
J Mol Diagn
; 24(4): 351-364, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35176488
17.
Differential expression of C5aR1 and C5aR2 in innate and adaptive immune cells located in early skin lesions of bullous pemphigoid patients.
Front Immunol
; 13: 942493, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36466856
18.
Identification and characterization of INCB9471, an allosteric noncompetitive small-molecule antagonist of C-C chemokine receptor 5 with potent inhibitory activity against monocyte migration and HIV-1 infection.
J Pharmacol Exp Ther
; 338(1): 228-39, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21459966
19.
Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib.
Cancer Discov
; 11(2): 326-339, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33218975
20.
Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor.
J Med Chem
; 64(15): 10666-10679, 2021 08 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34269576